lixisenatide AVE0010

DRUG5 trials

Sponsors

Sanofi

Conditions

Type 1 Diabetes MellitusType 2 Diabetes MellitusType II Diabetes Mellitus

Phase 1

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

CompletedNCT01146678

SanofiType 1 Diabetes Mellitus

Start: 2010-06-30End: 2011-01-31Target: 22Updated: 2011-03-02

Phase 2

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

TerminatedNCT02274740

SanofiType II Diabetes Mellitus

Start: 2015-04-30End: 2015-08-31Updated: 2017-01-30

Phase 3

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

CompletedNCT01940965

SanofiType 2 Diabetes Mellitus

Start: 2013-09-30End: 2015-07-31Updated: 2015-08-04

Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

CompletedNCT01960179

SanofiType 2 Diabetes Mellitus

Start: 2013-11-30End: 2015-03-31Updated: 2015-04-09

Phase 4

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

CompletedNCT02200991

SanofiType 2 Diabetes Mellitus

Start: 2014-08-31End: 2015-11-30Updated: 2016-10-05

Related Papers

Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.

2017-06-124 citations

Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).

2017-04-276 citations